levoleucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   30 Trials   30 Trials   224 News 
37 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
levoleucovorin calcium / Generic mfg.
2012-005748-12: D2 Resection and HIPEC (Hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma. A national randomized and multicentric phase III study INTERET DE LA CHIMIOHYPERTHERMIE INTRAPERITONEALE (CHIP) ADJUVANTE A L’OXALIPLATINE DANS LE TRAITEMENT CURATIF DES CANCERS GASTRIQUES AVANCES. ETUDE NATIONALE, RANDOMISEE ET MULTICENTRIQUE DE PHASE III.

Ongoing
3
322
Europe
5 Fluorouracilo, L01B1A, Solution for injection/infusion, Oxaliplatin, 5 Fluorouracilo, Levofolinate Calcium
Hospices Civils de Lyon, Ministère de la Santé, Hospices Civils de Lyon
Gastric adenocarcinoma, Stomach cancer, Diseases [C] - Digestive System Diseases [C06]
 
 
LYNK-003, NCT04456699 / 2019-000698-22: Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/)

Hourglass Jan 2024 - Dec 2024 : Data from P3 LYNK-003 trial for 1L colorectal cancer
Jan 2024 - Dec 2024: Acceptance of regulatory submission for CRC (based on LYNK-003 trial)
Checkmark Termination of P3 LYNK-003 trial in unresectable or metastatic CRC
Jul 2022 - Jul 2022: Termination of P3 LYNK-003 trial in unresectable or metastatic CRC
Completed
3
335
Europe, Canada, Japan, US, RoW
Olaparib, LYNPARZA^TM, 5-FU, Fluorouracil, Adrucil, Efudex, Bevacizumab, MVASI^TM, Avastin, Capecitabine, XELODA^®, Leucovorin/ levoleucovorin, Folinic Acid, Fusilev^®, Khapzory^TM
Merck Sharp & Dohme LLC, AstraZeneca
Metastatic Colorectal Cancer
03/23
11/23
LIBImAb, NCT04776655: Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB

Recruiting
3
280
Europe
Bevacizumab, Avastin, Cetuximab, Erbitux, 5-FU, 5 Fluorouracil, Irinotecan, Irinotecano, Calcium levofolinate, Levofolinic acid
Azienda Unità Sanitaria Locale Reggio Emilia, Istituto Di Ricerche Farmacologiche Mario Negri, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation
04/23
04/24
PARADIGM biomarker, NCT02394834: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of MFOLFOX6 + Bevacizumab Versus MFOLFOX6 + Panitumumab Therapy in Patients with Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Active, not recruiting
3
757
Japan
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
Takeda
Colorectal Cancer
03/25
03/25
OrigAMI-2, NCT06662786: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Recruiting
3
1000
Europe, Japan, US, RoW
Amivantamab, JNJ-61186372, Cetuximab, Erbitux, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin, Irinotecan Hydrochloride
Janssen Research & Development, LLC
Colorectal Neoplasms
12/28
12/32
BREAKWATER, NCT04607421 / 2020-001288-99: A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Calendar Jan 2025 - Dec 2025: Approval for 1L BRAFV600E metastatic CRC (based on BREAKWATER trial)
Checkmark Data from the safety lead-in portion of BREAKWATER trial in BRAF V600E-mutant mCRC at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from the safety lead-in portion of BREAKWATER trial in BRAF V600E-mutant mCRC at ASCO-GI 2023
Active, not recruiting
3
816
Europe, Canada, Japan, US, RoW
Encorafenib, Braftovi, PF-07263896, LGX818, ONO-7702, Cetuximab, Erbitux, Oxaliplatin, Eloxatin, Irinotecan, Campostar, Leucovorin, Wellcovorin, Fusilev, Khapzory, 5-FU, Fluorouracil, Capecitabine, Xeloda, Bevacizumab, Zirabev
Pfizer, Ono Pharmaceutical Co. Ltd, Merck KGaA, Darmstadt, Germany, Eli Lilly and Company
Neoplasms
01/25
12/26
OrigAMI-3, NCT06750094: A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Recruiting
3
700
US, RoW
Amivantamab, JNJ-61186372, Cetuximab, Erbitux, Bevacizumab, Avastin, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Folinic acid, Irinotecan
Janssen Research & Development, LLC
Colorectal Neoplasms
12/27
04/29
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
LEAP-014, NCT04949256 / 2020-001911-26: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/)

Hourglass Jan 2022 - Jan 2022 : Data from LEAP trial in combination with Keytruda for esophageal squamous cell carcinoma at ASCO-GI 2022
Recruiting
3
862
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, MK-7902, E7080, LENVIMA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Paclitaxel, TAXOL®, ONXAL®
Merck Sharp & Dohme LLC, Eisai Inc.
Metastatic Esophageal Squamous Cell Carcinoma
12/25
12/25
LEAP-015, NCT04662710 / 2020-001990-53: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/)

Active, not recruiting
3
890
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Lenvatinib, MK-7902, E7080, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin), 5-FU
Merck Sharp & Dohme LLC, Eisai Inc.
Advanced/Metastatic Gastroesophageal Adenocarcinoma
02/26
02/26
KEYNOTE 975, NCT04210115 / 2019-002006-51: Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Calendar Jan 2026 - Dec 2026: Data from KEYNOTE-975 trial for esophageal cancer
Active, not recruiting
3
703
Europe, Canada, Japan, US, RoW
pembrolizumab, MK-3475, KEYTRUDA®, placebo, Normal saline solution, cisplatin, PLATINOL®, 5-FU, ADRUCIL®, radiotherapy, leucovorin, calcium folinate, folinic acid, levoleucovorin, FUSILEV®, calcium levofolinate, levofolinic acid, oxaliplatin, ELOXATIN®
Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
02/27
02/27
2013-000770-30: Phase II study of up-front chemotherapy and neo-adjuvant short-course radiotherapy for resectable rectal carcinoma

Not yet recruiting
2
50
Europe
oxaliplatin, 5-fluorouracil, levofolinate, Concentrate for solution for infusion, Solution for infusion, Powder for solution for infusion
IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO, IRCCS IRST
resectable rectal carcinoma, resectable rectal carcinoma, Diseases [C] - Cancer [C04]
 
 
2017-000741-46: TWO CHEMOTHERAPY REGIMENS PLUS OR MINUS BEVACIZUMAB IN PATIENTS WITH PANCREATIC NEUROENDOCRINE TUMORS

Not yet recruiting
2
140
Europe
Bevacizumab, Capecitabine, Temozolomide, 5 FU, Streptozocine, Levofolinate de calcium, Concentrate and solvent for solution for infusion, Film-coated tablet, Capsule, hard, Solution for infusion, Powder for solution for injection, , Bevacizumab
Gustave Roussy, PHRC
Pancreatic well differentiated neuroendocrine tumors (NET), Pancreatic neuroendocrine tumors, Diseases [C] - Cancer [C04]
 
 
CLIMB, NCT03698461: Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab

Completed
2
20
RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Oxaliplatin, Levoleucovorin, 5-FU, 5-fluorouracil
Asan Medical Center, Hoffmann-La Roche
Colorectal Neoplasms, Neoplasm Metastasis, Colonic Neoplasms, Rectal Neoplasms
12/21
10/23
SENECA, NCT03387592 / 2016-000767-17: CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

Recruiting
2
112
Europe
CPT-11, Calcio levofolinate, 5-Fluorouracil, Capecitabine, Temozolomide
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Neuroendocrine Carcinoma
01/22
01/22
NCT06197438: Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

Not yet recruiting
2
36
NA
Tislelizumab, Oxaliplatin, Levo-Leucovorin, 5-fluorouracil, Irinotecan Hydrochloride, Paclitaxel
Fujian Cancer Hospital
Gastric Cancer
04/24
04/25
NCT05839470: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Recruiting
2
20
RoW
cadonilimab, irinotecan, Oxaliplatin, leucovorin or levoleucovorin, 5-FU
Fujian Cancer Hospital
Colorectal Cancer
03/24
03/25
NCT06225999: Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas

Active, not recruiting
2
41
Japan
Irinotecan liposome injection (S095013), MM-398, Nal-IRI, BAX2398, PEP02, liposomal irinotecan, Oxaliplatin, LLV (levoisomer form of leucovorin), 5- FU (5-Fluorouracil)
Institut de Recherches Internationales Servier
Metastatic Adenocarcinoma of the Pancreas
08/25
01/26
NuTide:323, NCT05678257 / 2022-001459-17: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

Terminated
2
182
Europe, US
Fosifloxuridine Nafalbenamide, NUC-3373, Nucleotide analogue, Leucovorin, Folinic acid, LV, Irinotecan, Campto, Camptosar, Bevacizumab, Avastin, Zirabev, 5-FU, 5FU, 5-fluorouracil, Fluorouracil
NuCana plc, NuCana plc
Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Neoplasm, Colorectal
08/24
08/24
2022-001459-17: A study of the effects of NUC-3373 in combination with standard anticancer drugs (NUFIRI-bev) compared with FOLFIRI-bev in patients with previously treated colorectal cancers that have spread into the surrounding tissue or to another part of the body. Estudio de los efectos del NUC3373 en combinación con fármacos anticancerosos estándar (NUFIRI-bev) comparado con FOLFIRI-bev en pacientes con cáncer colorrectal previamente tratados que se han extendido al tejido circundante o a otra parte del cuerpo.

Ongoing
2
171
Europe
NUC-3373 for infusion, 5-Fluorouracil, Irinotecan, Bevacizumab, Leucovorin, Levo-leucovorin, V03AF03, Concentrate for solution for infusion, Solution for infusion, Solution for injection, Irinotecan Hydrochloride 20mg/ml Concentrate for Solution for Infusion, Calcium Folinate 10mg/ml Injection, Normon calcium folinate 350 mg powder for solution for injection, Zirabev 25 mg/ml concentrate for solution for infusion, Fluorouracil 25mg/ ml Injection, Fluorouracil 50mg/ml Injection, FLUOROURACILE PFIZER 50 mg/ml, solution à diluer pour perfusion
NuCana plc, NuCana plc
Relapsed, unresectable, histologically or cytologically confirmed metastatic adenocarcinoma of colon or rectum with radiologically measurable disease. Adenocarcinoma metastásico de colon o recto recidivante, irresecable, confirmado histológica o citológicamente con enfermedad radiológicamente medible., Previously treated colorectal cancer that has spread from one part of the body to another and that cannot be removed surgically Cáncer colorrectal previamente tratado que se ha extendido de una parte del cuerpo a otra y que no puede ser extirpado quirúrgicamente., Diseases [C] - Cancer [C04]
 
 
NCT06700603: Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer

Not yet recruiting
2
48
NA
Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate
Rui-hua Xu, MD, PhD
Pancreatic Cancer
12/25
12/26
NCT02839915: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder

Active, not recruiting
2
56
US
Folinic Acid, Liquid levo-leucovorin, Placebo
Southwest Autism Research & Resource Center, Emory University, Harvard University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), State University of New York - Downstate Medical Center
Autism Spectrum Disorder
04/24
01/25
NCT04060017: Early Treatment of Language Impairment in Young Children with Autism Spectrum Disorder with Leucovorin Calcium

Recruiting
2
80
US
Levoleucovorin Calcium, L-leucovorin, L-leucovorin calcium, L-folinic acid, calcium salt, L-folinate, calcium salt, Placebo
Southwest Autism Research & Resource Center, State University of New York - Downstate Medical Center, United States Department of Defense
Autism Spectrum Disorder, Language Disorders
01/25
01/25
NCT04060030: Treatment of Social and Language Deficits with Leucovorin for Young Children with Autism

Recruiting
2
80
US
Levoleucovorin Calcium, L-leucovorin, L-leucovorin calcium, L-folinic acid, calcium salt, L-folinate, calcium salt, Placebo
Southwest Autism Research & Resource Center, Autism Speaks, State University of New York - Downstate Medical Center
Autism Spectrum Disorder, Language Disorders
01/25
01/25
NCT05945823: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Recruiting
2
66
Europe, US
Futibatinib, TAS-120, Pembrolizumab, MK-3475, KEYTRUDA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Irinotecan
Taiho Oncology, Inc.
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
01/25
05/25
EPOC2001, NCT04745988: An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer

Active, not recruiting
2
43
Japan
Lenvatinib 20mg, Pembrolizumab, Lenvatinib 8mg, Docetaxel, Oxaliplatin, Levofolinate, Fluorouracil
National Cancer Center Hospital East, Merck Sharp & Dohme LLC
Gastric Cancer
08/26
08/27
NuTide:302, NCT03428958: A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Completed
1/2
107
Europe, US
NUC-3373 + leucovorin, folinic acid, levoleucovorin, Nucleotide analogue, NUC-3373, NUFOX, Eloxatin, NUFOX + VEGF pathway inhibitor, Avastin, NUFOX + EGFR inhibitor, Erbitux, Vectibix, NUFIRI, Campto, Camptosar, NUFIRI + VEGF pathway inhibitor, NUFIRI + EGFR inhibitor, NUC-3373 + bevacizumab
NuCana plc
Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
03/24
03/24
SYLT-023, NCT05319639: Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Recruiting
1/2
20
RoW
Oxaliplatin, Levo-Leucovorin, 5-fluorouracil, Paclitaxel, Irinotecan, Tislelizumab
Fujian Cancer Hospital
Gastric Cancer Stage IV
12/23
12/24
NCT06428409: A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A)

Recruiting
1/2
130
Europe, Canada, Japan, US, RoW
Sacituzumab tirumotecan, MK-2870, SKB264, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures
Merck Sharp & Dohme LLC
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
12/28
12/28
NuTide:303, NCT05714553: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Recruiting
1/2
91
Europe
Fosifloxuridine Nafalbenamide, NUC-3373, Nucleotide analogue, Leucovorin, Folinic acid, Levo-leucovorin, Pembrolizumab, Keytruda, Docetaxel, Taxotere, Docecad, Docefrez
NuCana plc
Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer, Melanoma, Classical Hodgkin Lymphoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Subungual Squamous Cell Carcinoma, Oesophageal Carcinoma, MSI-H Colorectal Cancer, Gastric Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Pleural Mesothelioma
01/25
01/25
KEYMAKER-06C, NCT06469944: Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Recruiting
1/2
130
Europe, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Sacituzumab Tirumotecan (sac-TMT), MK-2870, SKB264, Capecitabine, XELODA, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, 5-FU, ADRUCIL®
Merck Sharp & Dohme LLC
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
01/27
04/29
NCT06547385: Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer

Active, not recruiting
1
40
Japan
ONO-4578, ONO-4538, Nivolumab, Capecitabine, XELODA, Oxaliplatin, ELPLAT, Fluorouracil, 5-FU, Calcium Levofolinate Hydrateb, ISOVORIN, Bevacizumab, AVASTIN
Ono Pharmaceutical Co. Ltd
Colorectal Cancer
10/27
10/27
ONO-4578-04, NCT06538207: An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Active, not recruiting
1
46
Japan
ONO-4578, ONO-4538, Nivolumab, Oxaliplatin, Levofolinate, Irinotecan, Fluorouracil, Gemcitabine, Nab-Paclitaxel
Ono Pharmaceutical Co. Ltd
Metastatic Pancreatic Cancer
10/24
03/25
NCT06532344: An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Active, not recruiting
1
32
Japan
ONO-7913, Magrolimab, ONO-4538, Nivolumab, Oxaliplatin, Levofolinate, Irinotecan, Fluorouracil
Ono Pharmaceutical Co. Ltd
Metastatic Pancreatic Cancer
12/26
12/26
ONO-7913-04, NCT06540261: The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Active, not recruiting
1
65
Japan
ONO-7913, Magrolimab, ONO-4538, Nivolumab, Fluorouracil, Oxaliplatin, Levofolinate, Bevacizumab, Cetuximab
Ono Pharmaceutical Co. Ltd
Unresectable Colorectal Cancer
12/27
12/27
LAP-NET1, NCT05546853: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Active, not recruiting
1
52
Europe
NP137, Oxaliplatin, Irinotecan, Calcium levofolinate, 5 FU
University Hospital, Grenoble, NETRIS Pharma
Pancreatic Ductal Adenocarcinoma
03/26
03/27
ChiCTR2300078700: Clinical study on the efficacy and safety of regimen containing 5-FU/ levoleucovorin (Zuoyu ®️) in the first-line treatment of advanced gastric cancer

Recruiting
1
52
 
Simultaneous infusion of Left folic acid and 5-FU
Jiangnan University Affiliated Hospital; Jiangnan University Affiliated Hospital, Self-raised
Advanced gastric cancer
 
 

Download Options